Project Details
Projekt
EXC 62: From Regenerative Biology to Reconstructive Therapy (REBIRTH)
Subject Area
Medicine
Basic Research in Biology and Medicine
Basic Research in Biology and Medicine
Term
from 2006 to 2019
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 24102914
With the enthusiastic support of six important partner institutions, Hannover Medical School (MHH) established a cluster of excellence in the area of Regenerative Biology and Reconstructive Therapies (REBIRTH). Our programme integrates excellent training with innovative science and experimental as well as clinical medicine. Interactive basic research projects are designed to identify and evaluate cellular and molecular mediators that stimulate regeneration. We study both intrinsic pathways and milieu-dependent mechanisms which control epigenetic reprogramming, cell expansion, differentiation, migration, organogenesis and disease-specific regeneration.
Driven by these insights, we test new approaches for regenerative therapies using novel (if possible somatic) cell sources which we engineer applying genetic, epigenetic, as well as scaffold-based principles. Expertise in various fields of engineering, chemistry, biophotonics and nanotechnology will support and supplement our research and development. Toward patient-focussed, applied studies, the existing wide range of certified respective accredited facilities for Good Practice (laboratory, manufacturing and clinical), and close industrial collaborations will be further expanded. Upscaling technologies and pro-active biosafety assessment complete our translational activities. Based upon MHH's recent key achievements and priorities we focus on disorders of blood (including immunity), heart, respiratory tract, liver and pancreatic beta cells. Our animal models span a wide range from rodents via domestic animals to non-human primates, including associated stem cell technologies. Carefully designed clinical trials are already being conducted and will be further expanded. Thereby, REBIRTH will represent an optimal partner for other domestic and international centres in regenerative medicine. Last but not least, sustainable training and diversity programmes represent major objectives of our concept.
Driven by these insights, we test new approaches for regenerative therapies using novel (if possible somatic) cell sources which we engineer applying genetic, epigenetic, as well as scaffold-based principles. Expertise in various fields of engineering, chemistry, biophotonics and nanotechnology will support and supplement our research and development. Toward patient-focussed, applied studies, the existing wide range of certified respective accredited facilities for Good Practice (laboratory, manufacturing and clinical), and close industrial collaborations will be further expanded. Upscaling technologies and pro-active biosafety assessment complete our translational activities. Based upon MHH's recent key achievements and priorities we focus on disorders of blood (including immunity), heart, respiratory tract, liver and pancreatic beta cells. Our animal models span a wide range from rodents via domestic animals to non-human primates, including associated stem cell technologies. Carefully designed clinical trials are already being conducted and will be further expanded. Thereby, REBIRTH will represent an optimal partner for other domestic and international centres in regenerative medicine. Last but not least, sustainable training and diversity programmes represent major objectives of our concept.
DFG Programme
Clusters of Excellence
Applicant Institution
Medizinische Hochschule Hannover
Co-Applicant Institution
Gottfried Wilhelm Leibniz Universität Hannover
Participating Institution
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin (ITEM); Helmholtz-Zentrum für Infektionsforschung (HZI); Friedrich-Loeffler-Institut
Bundesforschungsinstitut für Tiergesundheit
Institut für Nutztiergenetik; Laser Zentrum Hannover e.V. (LZH); Max-Planck-Institut für molekulare Biomedizin
Bundesforschungsinstitut für Tiergesundheit
Institut für Nutztiergenetik; Laser Zentrum Hannover e.V. (LZH); Max-Planck-Institut für molekulare Biomedizin
Spokespersons
Professor Dr. Axel Haverich, until 11/2018; Professor Thomas Thum, Ph.D.
Participating Researchers
Professor Dr. Johann Bauersachs; Professor Dr. Christopher Baum; Professor Dr. Tobias Cantz; Professor Dr. Boris Chichkov; Dr. Gerald Dräger; Professor Dr. Wolfgang Ertmer; Professor Dr. Reinhold Förster; Professor Dr. Arnold Ganser; Professorin Dr. Rita Gerardy-Schahn; Professor Dr. Achim Gossler; Professorin Dr. Denise Hilfiker-Kleiner; Professor Dr. Andreas Kirschning; Professor Dr. Andreas Kispert; Professor Dr. Michael Peter Manns; Professor Dr. Ulrich Martin; Professor Dr. Heiner Niemann; Professor Dr. Thomas Scheper; Professorin Dr. Brigitte Schlegelberger; Professor Dr. Reinhold Ernst Schmidt (†); Professor Dr. Hans Robert Schöler; Professorin Julia Skokowa, Ph.D.; Professorin Dr. Renata Stripecke; Professorin Dr. Dagmar Wirth; Professor Dr. Kai Christoph Wollert
